IT Stocks Under AI Pressure; Pharma and Banks Gain Traction

TECHNOLOGY
Whalesbook Logo
AuthorAnanya Iyer|Published at:
IT Stocks Under AI Pressure; Pharma and Banks Gain Traction

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • Quarterly Results
  • Concall Announcements
  • New Orders & Big Deals
  • Capex Announcements
  • Bulk Deals
  • And much more

Indian IT stocks face selling pressure as new AI coding tools spark concerns over software service demand. Meanwhile, investors are rotating into Pharma and Banking sectors for stability.

What Happened

Indian information technology stocks have come under pressure following the release of advanced artificial intelligence models by Anthropic, specifically the Claude Fabel 5 and Mythos 5. These tools are designed to automate complex coding tasks, which has sparked immediate concerns among investors about the future demand for traditional software development and maintenance services. Companies such as Infosys, Tata Consultancy Services (TCS), and Tech Mahindra saw their share prices experience a downturn as the market re-evaluates the growth outlook for the IT sector in an AI-dominated environment.

Why Investors Are Cautious

The IT sector in India has historically relied on the "billable hour" model, where revenue is directly tied to the number of engineers and the time spent on writing and maintaining code. The rise of AI models capable of writing, debugging, and maintaining software at a high speed poses a direct challenge to this business model. Investors are worried that if corporate clients can complete software projects using AI tools at a fraction of the cost, the revenue growth of major Indian IT companies could slow down significantly. This apprehension has led to a reduction in investor interest, as the market tries to understand how these firms will adapt to a world where AI performs tasks previously handled by human teams.

The Shift to Pharma and Banks

As capital flows out of the IT sector, it is finding a home in the pharmaceutical and banking sectors. This rotation is often driven by investors seeking safety or domestic growth drivers that are less exposed to global tech disruption. Unlike the IT sector, which is currently facing a sentiment-driven reassessment due to AI, the pharmaceutical sector is seen as a defensive play. Companies like Torrent Pharma and Gland Pharma have attracted attention due to their stable demand profiles and ability to maintain margins. Similarly, private sector banks, including Axis Bank and ICICI Bank, are viewed as beneficiaries of domestic economic growth, showing resilience despite the volatility seen in other parts of the market.

Understanding Market Rotation

Market rotation is a common phenomenon where investors move money from one sector to another based on changing risks and growth prospects. When a dominant sector like IT faces a structural threat—or even just the perception of one—investors often reallocate capital to sectors with more predictable earnings. For shareholders, this means that while the IT sector may be experiencing a valuation correction, other sectors like Pharma and Banking are becoming preferred choices for those prioritizing stability over high-growth tech exposure.

Risks and Sector Context

Investors should keep in mind that the impact of AI on IT is still evolving. While automation can threaten legacy revenue, many IT firms are also adopting AI to improve their own internal efficiency and profit margins. The risk for shareholders is that if the sector fails to pivot quickly enough, the price-to-earnings (P/E) multiples—which have traditionally been high for IT stocks—could compress further as growth expectations are dialed back. Conversely, for the banking and pharma sectors, the primary risks remain regulatory changes, interest rate cycles, and the execution of their own business strategies, rather than the immediate tech-driven disruption facing software firms.

What Investors Should Track

The most important monitorable for investors is the commentary from management in IT firms regarding client spending on generative AI. Investors should look for evidence that these companies are successfully transitioning to high-value AI consulting work rather than just losing traditional coding contracts. For the banking and pharma sectors, tracking the consistency of quarterly earnings and credit growth (for banks) or product pipeline approvals (for pharma) will be crucial to see if their current outperformance can be sustained.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Disclaimer:This article is published for informational purposes only. While reasonable efforts are made to ensure accuracy, completeness, and timeliness, readers are encouraged to independently verify information before making any decisions based on the content. The views and information presented are subject to editorial review and may be updated without notice.